Active Ingredient(s): Atezolizumab
FDA Approved: * May 18, 2016
Pharm Company: * GENENTECH INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tecentriq Overview

Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC).[2] It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).[4] The most common side effects when used on its own include tired...

Read more Tecentriq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Atezolizumab

Recent Tecentriq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 1200mg/20ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tecentriq: (2 results)

Sorted by National Drug Code
  • 50242-917 Tecentriq 1200 mg/20ml Intravenous Injection, Solution by Genentech, Inc.
  • 50242-918 Tecentriq 840 mg/14ml Intravenous Injection, Solution by Genentech, Inc.

Other drugs which contain Atezolizumab or a similar ingredient: (1 result)